PROSCAR (finasteride)
PROSCAR is indicated for the treatment of Benign Prostatic Hyperplasia; Acute Urinary Retention.
How PROSCAR Works
Finasteride is a competitive and specific inhibitor of the Type II 5α-reductase enzyme, which is responsible for metabolizing testosterone into dihydrotestosterone (DHT) in the prostate, liver, and skin. Because the development and enlargement of the prostate gland are dependent on DHT, reducing its levels helps manage BPH. Finasteride binds with the enzyme to form a stable complex with an extremely slow turnover rate and has no affinity for androgen receptors.
Details
- Status
- Prescription
- First Approved
- 1992-06-19
- Routes
- ORAL
- Dosage Forms
- TABLET
PROSCAR Approval History
What PROSCAR Treats
2 indicationsPROSCAR is approved for 2 conditions since its original approval in 1992. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Benign Prostatic Hyperplasia
- Acute Urinary Retention
PROSCAR Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to PROSCAR
3 of 12FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
18 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT06944145 | 2025P000440 R01DK142211 | Ph 2 | recruiting | New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia |
| NCT02703220 | PULM-008-14F | Ph 4 | recruiting | Sleep Apnea in Elderly |
| NCT01227993 CSC-Ext results posted | 110012 11-EI-0012 | Ph 1, Ph 2 | completed | Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy |
| NCT00736645 results posted | CDR0000611962 RPCI I 104607 | Ph 2 | completed | Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer |
| NCT02248701 results posted | B1449-R 1I01RX001449-01A1 | Ph 2 | terminated | Testosterone Plus Finasteride Treatment After Spinal Cord Injury |
| NCT02548117 | 03-15-40-10 | Ph 3 | withdrawn | H-36731: Finasteride in Management of Elevated Red Blood Cells |
| NCT03004469 results posted | PM1541 | Ph 3 | completed | Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia |
| NCT02781311 results posted | 1922-201-002 | Ph 2 | completed | A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males |
| NCT01534351 results posted | 0906A-149 | Ph 3 | terminated | Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2) |
| NCT00564460 | E-2007 | Ph 3 | withdrawn | On Label, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Finasteride in Patients Undergoing Transurethral Resection of the Prostate (TURP) |
| NCT01296672 results posted | ROI 10-352H R01CA138627 | Ph 4 | completed | 3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer |
| NCT00837252 results posted | 090075 09-EI-0075 | Ph 1, Ph 2 | completed | Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy |
| NCT00542243 Prostress | 07-0499-B | Ph 3 | completed | A Trial of PROSCAR (Finasteride) Versus Placebo in Men With an Initial Negative Prostate Biopsy |
| NCT01585441 results posted | 120119 12-EI-0119 | Ph 2 | terminated | Finasteride for Chronic Central Serous Chorioretinopathy |
| NCT00600691 | H07-01188 Health Canada Control #118638, Merck Frosst #IISP #P2587 | Ph 2 | terminated | The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy |
| NCT01139762 results posted | 13529 H6D-CR-LVIW | Ph 3 | completed | A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms |
| NCT00663793 ORAL-T-6 results posted | 33738-B U54HD42456-06, K23HD045386 | Ph 1 | completed | ORAL T-6: Oral Androgens in Man-6 |
| NCT01052870 | HairDx2009 | Ph 1 | completed | Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
PROSCAR FDA Label Details
Indications & Usage
FDA Label (PDF)PROSCAR is indicated for the treatment of Benign Prostatic Hyperplasia; Acute Urinary Retention.
Track PROSCAR with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.